brains year effect size drug unprecedented says paper co author roger nitsch president founder zurich based neurimmune initially developed aducanumab drug increased risk brain hemorrhage potentially dangerous fluid shifts brain forcing balancing act effectiveness patients ability tolerate high dose researchers able catch early signs effect known amyloid related imaging abnormalities aria mri brain scans salloway says trial suffered irreversible harm trial small reduction brain amyloid difference everyday functioning participants indications drug slowed cognitive functional decline received highest dose months trial results public meetings new publication offers depth marks time results peer reviewed presented comprehensively authors said august 30 news conference